FDA Grants Tolebrutinib Breakthrough Therapy for Nonrelapsing Secondary Progressive Multiple Sclerosis

Published Date: 19 Dec 2024

Findings from the ongoing PERSEUS phase 3 study of tolebrutinib in primary progressive multiple sclerosis are anticipated to be reported in the second half of 2025.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.

2.

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

3.

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

4.

An inoperable locally advanced NSCLC trial dubbed "Practice Changing".

5.

CDC Alerts on Dramatic Rise in Human Parvovirus B19


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot